Lynn A. Tetrault
CIK: 0001645512
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (28 total)
- Jun 30, 2026ALMS
ALUMIS INC.
Award(A)Direct3.6K shares- - Jun 24, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectStock Option (right to buy)
3.7K shares- - Jun 24, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Units
2.3K shares- - Jun 23, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct4.7K shares- - Jun 22, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct37K shares at avg. $28.27$1.0M - Jun 22, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct37K shares at avg. $100.32$3.7M - Jun 15, 2026NEO
NEOGENOMICS INC
Sale(S)Direct5.3K shares at avg. $11.10$59K - Jun 9, 2026NEO
NEOGENOMICS INC
Sale(S)Direct5.3K shares at avg. $11.29$60K - Jun 1, 2026NEO
NEOGENOMICS INC
Exercise(M)Direct23.1K shares- - Jun 1, 2026NEO
NEOGENOMICS INC
Award(A)DirectRestricted Stock Unit
16K shares- - Jun 1, 2026NEO
NEOGENOMICS INC
Award(A)DirectStock Option (Right to Buy)
11.1K shares- - Jul 30, 2025ALMS
ALUMIS INC.
Award(A)DirectStock Option (Right to Buy)
49.8K shares- - Jun 24, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Units
4.7K shares- - Jun 24, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectStock Option (right to buy)
7K shares- - Jun 18, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct4K shares- - Jun 1, 2025NEO
NEOGENOMICS INC
Award(A)DirectRestricted Stock Unit
23.1K shares- - Jun 1, 2025NEO
NEOGENOMICS INC
Exercise(M)Direct12.3K shares- - Jun 1, 2025NEO
NEOGENOMICS INC
Award(A)DirectStock Option (Right to Buy)
16.1K shares- - May 21, 2025SLRN
ACELYRIN, Inc.
Disposition(D)DirectDirector Stock Option (right to buy)
43.7K shares- - May 21, 2025SLRN
ACELYRIN, Inc.
Disposition(D)DirectDirector Stock Option (right to buy)
90K shares- - May 9, 2025NEO
NEOGENOMICS INC
Purchase(P)Indirect7K shares at avg. $8.14$57K - Sep 10, 2024RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct7.5K shares at avg. $18.99$142K - Sep 10, 2024RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct10K shares at avg. $4.15$42K - Sep 10, 2024RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct350 shares at avg. $50.60$18K - Sep 10, 2024RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct8.7K shares at avg. $50.20$435K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 30, 2026 |  ALMS ALUMIS INC. | Award(A) | 3,553 | - | $0 | Direct |
| Jun 24, 2026 |  RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Stock Option (right to buy) | 3,691 | - | - | Direct |
| Jun 24, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Restricted Stock Units | 2,324 | - | - | Direct |
| Jun 23, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 4,712 | - | $0 | Direct |
| Jun 22, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 37,000 | $28.27 | $1,045,990 | Direct |
| Jun 22, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 37,000 | $100.32 | $3,711,896 | Direct |
| Jun 15, 2026 |  NEO NEOGENOMICS INC | Sale(S) | 5,307 | $11.10 | $58,908 | Direct |
| Jun 9, 2026 | NEO NEOGENOMICS INC | Sale(S) | 5,307 | $11.29 | $59,916 | Direct |
| Jun 1, 2026 | NEO NEOGENOMICS INC | Exercise(M) | 23,077 | - | $0 | Direct |
| Jun 1, 2026 | NEO NEOGENOMICS INC | Award(A) Restricted Stock Unit | 15,970 | - | - | Direct |
| Jun 1, 2026 | NEO NEOGENOMICS INC | Award(A) Stock Option (Right to Buy) | 11,069 | - | - | Direct |
| Jul 30, 2025 | ALMS ALUMIS INC. | Award(A) Stock Option (Right to Buy) | 49,800 | - | - | Direct |
| Jun 24, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Restricted Stock Units | 4,712 | - | - | Direct |
| Jun 24, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Stock Option (right to buy) | 7,037 | - | - | Direct |
| Jun 18, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 4,000 | - | - | Direct |
| Jun 1, 2025 | NEO NEOGENOMICS INC | Award(A) Restricted Stock Unit | 23,077 | - | - | Direct |
| Jun 1, 2025 | NEO NEOGENOMICS INC | Exercise(M) | 12,254 | - | - | Direct |
| Jun 1, 2025 | NEO NEOGENOMICS INC | Award(A) Stock Option (Right to Buy) | 16,107 | - | - | Direct |
| May 21, 2025 |  SLRN ACELYRIN, Inc. | Disposition(D) Director Stock Option (right to buy) | 43,680 | - | - | Direct |
| May 21, 2025 | SLRN ACELYRIN, Inc. | Disposition(D) Director Stock Option (right to buy) | 89,955 | - | - | Direct |
| May 9, 2025 | NEO NEOGENOMICS INC | Purchase(P) | 7,000 | $8.14 | $56,974 | Indirect |
| Sep 10, 2024 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 7,501 | $18.99 | $142,444 | Direct |
| Sep 10, 2024 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 10,000 | $4.15 | $41,500 | Direct |
| Sep 10, 2024 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 350 | $50.60 | $17,710 | Direct |
| Sep 10, 2024 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 8,661 | $50.20 | $434,796 | Direct |
1-25 of 28 transactions
About TETRAULT LYNN A.
TETRAULT LYNN A. (SEC CIK 0001645512) files insider reports with the SEC as Director of ALUMIS INC. (ALMS), Director of RHYTHM PHARMACEUTICALS, INC. (RYTM) and Director of NEOGENOMICS INC (NEO). Signal8 also holds filings tied to 1 other company.
Signal8 holds 14 ownership filings by TETRAULT LYNN A. (1 Form 3, 13 Form 4), filed between Sep 11, 2024 and Jul 2, 2026. Those filings report 28 transactions, from Sep 9, 2024 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on TETRAULT LYNN A.'s filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by TETRAULT LYNN A.
- Jun 30, 2026: Grant or award of ALMS shares (Form 4, code A).
- Jun 24, 2026: Grants or awards of RYTM derivative securities (2 lines, Form 4, code A).
- Jun 23, 2026: Option exercise of RYTM shares (Form 4, code M).
- Jun 22, 2026: Option exercise of RYTM shares (Form 4, code M).
- Jun 22, 2026: Open-market sale of RYTM shares (Form 4, code S).
Other insiders filing for ALUMIS INC. (ALMS)
- AKKARAJU SRINIVAS, Director
- Schroer John R., Chief Financial Officer
- Pangali Sanam, Chief Legal Officer
- Hardiman Roy C., Chief Business & Strategy Ofcr
- Goldstein David M, Chief Scientific Officer
- Drappa Jorn, Chief Medical Officer